DBVT
DBV Technologies Surges Ahead in Q3 2026: Regulatory Milestones and Quality Assurance in Focus
DBV Technologies, a pioneering biotech company specializing in allergy treatments, has made significant strides in its third quarter of 2026, as revealed during the company's recent conference call. The key highlight of this period was the submission of a BLA (Biologics License Application) for the VIASKIN Peanut patch,